Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1656 views | HTML 2251 views | ?
Darío García-Carracedo1,*, Maria Ángeles Villaronga2,*, Saúl Álvarez-Teijeiro2, Francisco Hermida-Prado2, Iñigo Santamaría3, Eva Allonca2, Laura Suárez-Fernández2, Maria Victoria Gonzalez4, Milagros Balbín3, Aurora Astudillo4, Pablo Martínez-Camblor5, Gloria H. Su1,6,7,, Juan Pablo Rodrigo2, Juana María García-Pedrero2
1Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
2Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain
3Department of Molecular Oncology, Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain
4Department of Pathology, Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
5Biostatistics Unit, Hospital Universitario Central de Asturias, Oviedo, Spain
6Department of Pathology, Columbia University Medical Center, New York, NY, USA
7Departments of Otolaryngology/Head and Neck Surgery, Columbia University Medical Center, New York, NY, USA
*These authors have contributed equally to this work
Juan Pablo Rodrigo, email: [email protected]
Juana María García-Pedrero, email: [email protected]
Keywords: HNSCC, prognosis, PIK3CA mutation, S6 phosphorylation, immunohistochemistry
Received: September 17, 2015 Accepted: March 28, 2016 Published: April 23, 2016
The PI3K/AKT/mTOR signaling pathway has emerged as one of the most frequently deregulated in head and neck squamous cell carcinomas (HNSCC). Numerous alterations of various upstream and downstream components have been described; however, their prognostic significance and impact on HNSCC patient survival remains to be established. This was addressed using an unbiased cohort of 93 consecutive and homogeneous surgically treated HNSCC patients and results confirmed in 432 HNSCC patients. Our findings reveal the high prevalence of S6 phosphorylation, a surrogate marker of mTORC1 activation, in HNSCC specimens (>70%) and, more importantly, demonstrate its relevance on clinical outcome. Phosphorylation of ribosomal protein S6 on either Ser235/236 or Ser240/244 was consistently and significantly correlated with favorable prognosis, although with differences depending on the tumor site. Thus, p-S6 expression was significantly correlated with better disease-specific survival specifically in the subgroup of laryngeal carcinoma patients (P< 0.001). In addition, multivariate regression models revealed p-S6 to be an inverse and independent predictor of lymph-node metastasis (P= 0.004) and distant metastasis (P= 0.006). Taken together, this study unveils an unprecedented correlation of mTOR activation with improved clinical outcome in patients with laryngeal carcinomas and uncovers the potential of p-S6 expression as a good prognostic biomarker and an inverse predictor of lymph node and distant metastases. These results should be of broad interest as immunohistochemical detection of p-S6 may help to stratify patients and guide treatment decisions.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.